10:27 AM EDT, 06/04/2025 (MT Newswires) -- Sarepta Therapeutics ( SRPT ) said Wednesday that the US Food and Drug Administration has granted platform technology designation for the rAAVrh74 viral vector used in the company's investigational gene therapy SRP-9003 for limb-girdle muscular dystrophy type 2E/R4.

The company said the designation supports the development of rare disease therapies by streamlining the processes for drug product applications.

Shares of Sarepta were up more than 2% in recent trading Wednesday.

Price: 39.78, Change: +0.90, Percent Change: +2.31